Positive Phase 3 Topline Results for Early Parkinson's Drug

The novel drug P2B001 is superior to its individual components of pramipexole or rasagiline for early Parkinson's disease ― with less daytime sleepiness, new topline results suggest.
Medscape Medical News

source https://www.medscape.com/viewarticle/965583?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension